This move is archived. Current quotes and coverage live on the stock page.
Get MSCL alerts:
Investors are taking notice as Satellos Bioscience Inc. sees a notable uptick in its stock price.
Satellos Bioscience Inc. (MSCL.TO) has experienced a positive shift in its stock performance, rising by 3.24% in the last trading session. This increase comes amidst significant developments in the company's clinical programs, particularly in the treatment of Duchenne muscular dystrophy.
Investor takeaway: With the FDA Fast Track designation for its promising treatment SAT-3247 and a clear path towards a Nasdaq listing, Satellos appears to be positioning itself for growth, making it an intriguing option for investors focused on biotech innovation.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$277.51M
52W high
$18.98
52W low
$7.20
1W change
-5.29%
Beta
1.17
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 35.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+35.1% Upside
Current Price
C$13.08
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
54.8%
Annualized
90-Day Vol
74.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$15.64
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$13.88 | C$11.49 โ C$16.77 |
| 60 trading days | C$14.73 | C$11.28 โ C$19.25 |
| 90 trading days | C$15.64 | C$11.27 โ C$21.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. Closes at CA$10.53
The stock's market cap now stands at CA$222 million, reflecting growing investor interest.
Bull case
The recent FDA Fast Track designation for SAT-3247 could speed up the drug's development timeline. This means it might hit the market sooner, which could boost investor confidence.
Bear case
Despite the positive movement, investors should stay cautious. The company hasnโt generated profits yet and is heavily reliant on the success of its clinical trials.
FDA Fast Track Designation
Advertisement
The FDA's Fast Track designation for SAT-3247 is a significant milestone for Satellos Bioscience. This designation aims to speed up the development and review of drugs that treat serious conditions and fill an unmet medical need. This could lead to quicker access for patients and potentially boost the company's stock further.
Path to Nasdaq Listing
Satellos recently completed a 1-for-12 share consolidation to qualify for a Nasdaq listing. This move not only enhances the company's visibility but also attracts a broader range of institutional investors, which could lead to increased liquidity and better stock performance.
Clinical Advancements
The initiation of a Phase 2 study for SAT-3247 in pediatric patients marks a critical step in the company's clinical journey. With regulatory clearances in hand, focusing on treating Duchenne muscular dystrophy could position Satellos as a leader in this niche market, further solidifying investor confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
